Esbriet is a medicine used to treat adults with idiopathic pulmonary fibrosis (IPF). IPF is a long-term disease in which fibrous scar tissue continuously forms in the lungs, causing persistent cough, frequent lung infections and severe shortness of breath. ‘Idiopathic’ means that the cause of the disease is unknown. Esbriet contains the active substance pirfenidone.
Therapeutic Indication
### Therapeutic indication Esbriet is indicated in adults for the treatment of idiopathic pulmonary fibrosis.
Therapeutic Area (MeSH)
N/AATC Code
L04AX05
ATC Item
pirfenidone
Pharmacotherapeutic Group
Immunosuppressants
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| Pirfenidone | N/A | 吡非尼酮 |
EMA Name
Esbriet
Medicine Name
Esbriet
Aliases
N/ANo risk management plan link.
